Non-Tyrosine Kinase Inhibitors Market Report

Global and Region Non-Tyrosine Kinase Inhibitors Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 02, 2022
  • PAGES：230
  • REPORT CODE：GMM988310
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Non-Tyrosine Kinase Inhibitors market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Non-Tyrosine Kinase Inhibitorsmarket, defines the market attractiveness level of Non-Tyrosine Kinase Inhibitors market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Non-Tyrosine Kinase Inhibitors industry, describes the types of Non-Tyrosine Kinase Inhibitors market, the applications of major players and the market size, and deeply analyzes the current situation of the global Non-Tyrosine Kinase Inhibitors market and the development prospects and opportunities of Non-Tyrosine Kinase Inhibitors industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Non-Tyrosine Kinase Inhibitors market in Chapter 13.

    By Player:

    • Array BioPharma

    • Carna Biosciences

    • Daiichi Sankyo

    • Onconova Therapeutics

    • Jasco Pharmaceuticals

    • Eternity Bioscience

    • Pfizer

    • Celgene Corporation

    • AstraZeneca

    • Eli Lilly

    • Novartis

    • Roche

    • Astex Pharmaceuticals

    • Nerviano Medical Sciences

    • Merck KGaA

    • GlaxoSmithKline (GSK)

    • Cyclacel Pharmaceuticals

    By Type:

    • mTOR Inhibitors

    • RAF/MEK Inhibitors

    • CDK Inhibitors

    By End-User:

    • Liver Cancer

    • Respiratory Cancer

    • Brain Cancer

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Non-Tyrosine Kinase Inhibitors Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Non-Tyrosine Kinase Inhibitors Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Non-Tyrosine Kinase Inhibitors Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Non-Tyrosine Kinase Inhibitors Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Non-Tyrosine Kinase Inhibitors Market Analysis and Outlook to 2022

    • 7.1 Global Non-Tyrosine Kinase Inhibitors Consumption (2017-2022)

    • 7.2 United States Non-Tyrosine Kinase Inhibitors Consumption (2017-2022)

    • 7.3 Europe Non-Tyrosine Kinase Inhibitors Consumption (2017-2022)

    • 7.4 China Non-Tyrosine Kinase Inhibitors Consumption (2017-2022)

    • 7.5 Japan Non-Tyrosine Kinase Inhibitors Consumption (2017-2022)

    • 7.6 India Non-Tyrosine Kinase Inhibitors Consumption (2017-2022)

    • 7.7 South Korea Non-Tyrosine Kinase Inhibitors Consumption (2017-2022)

    8 Region and Country-wise Non-Tyrosine Kinase Inhibitors Market Analysis and Outlook to 2028

    • 8.1 Global Non-Tyrosine Kinase Inhibitors Consumption Forecast (2022-2028)

    • 8.2 United States Non-Tyrosine Kinase Inhibitors Consumption Forecast (2022-2028)

    • 8.3 Europe Non-Tyrosine Kinase Inhibitors Consumption Forecast (2022-2028)

    • 8.4 China Non-Tyrosine Kinase Inhibitors Consumption Forecast (2022-2028)

    • 8.5 Japan Non-Tyrosine Kinase Inhibitors Consumption Forecast (2022-2028)

    • 8.6 India Non-Tyrosine Kinase Inhibitors Consumption Forecast (2022-2028)

    • 8.7 South Korea Non-Tyrosine Kinase Inhibitors Consumption Forecast (2022-2028)

    9 Global Non-Tyrosine Kinase Inhibitors Market Outlook by Types and Applications to 2022

    • 9.1 Global Non-Tyrosine Kinase Inhibitors Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global mTOR Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global RAF/MEK Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global CDK Inhibitors Consumption and Growth Rate (2017-2022)

    • 9.2 Global Non-Tyrosine Kinase Inhibitors Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Liver Cancer Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Respiratory Cancer Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Brain Cancer Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Non-Tyrosine Kinase Inhibitors Market Outlook by Types and Applications to 2028

    • 10.1 Global Non-Tyrosine Kinase Inhibitors Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global mTOR Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global RAF/MEK Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global CDK Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Non-Tyrosine Kinase Inhibitors Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Liver Cancer Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Respiratory Cancer Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Brain Cancer Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Non-Tyrosine Kinase Inhibitors Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Non-Tyrosine Kinase Inhibitors Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Non-Tyrosine Kinase Inhibitors Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Non-Tyrosine Kinase Inhibitors Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Non-Tyrosine Kinase Inhibitors Market Competitive Analysis

    • 14.1 Array BioPharma

      • 14.1.1 Array BioPharma Company Details

      • 14.1.2 Array BioPharma Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Array BioPharma Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.2 Carna Biosciences

      • 14.2.1 Carna Biosciences Company Details

      • 14.2.2 Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Carna Biosciences Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.3 Daiichi Sankyo

      • 14.3.1 Daiichi Sankyo Company Details

      • 14.3.2 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.4 Onconova Therapeutics

      • 14.4.1 Onconova Therapeutics Company Details

      • 14.4.2 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.5 Jasco Pharmaceuticals

      • 14.5.1 Jasco Pharmaceuticals Company Details

      • 14.5.2 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.6 Eternity Bioscience

      • 14.6.1 Eternity Bioscience Company Details

      • 14.6.2 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.7 Pfizer

      • 14.7.1 Pfizer Company Details

      • 14.7.2 Pfizer Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Pfizer Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.8 Celgene Corporation

      • 14.8.1 Celgene Corporation Company Details

      • 14.8.2 Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Celgene Corporation Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.9 AstraZeneca

      • 14.9.1 AstraZeneca Company Details

      • 14.9.2 AstraZeneca Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 AstraZeneca Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.10 Eli Lilly

      • 14.10.1 Eli Lilly Company Details

      • 14.10.2 Eli Lilly Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Eli Lilly Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.11 Novartis

      • 14.11.1 Novartis Company Details

      • 14.11.2 Novartis Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Novartis Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.12 Roche

      • 14.12.1 Roche Company Details

      • 14.12.2 Roche Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Roche Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.13 Astex Pharmaceuticals

      • 14.13.1 Astex Pharmaceuticals Company Details

      • 14.13.2 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.14 Nerviano Medical Sciences

      • 14.14.1 Nerviano Medical Sciences Company Details

      • 14.14.2 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.15 Merck KGaA

      • 14.15.1 Merck KGaA Company Details

      • 14.15.2 Merck KGaA Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Merck KGaA Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.16 GlaxoSmithKline (GSK)

      • 14.16.1 GlaxoSmithKline (GSK) Company Details

      • 14.16.2 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.16.3 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Product and Service

    • 14.17 Cyclacel Pharmaceuticals

      • 14.17.1 Cyclacel Pharmaceuticals Company Details

      • 14.17.2 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.17.3 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Non-Tyrosine Kinase Inhibitors

    • Figure Non-Tyrosine Kinase Inhibitors Picture

    • Table Global Non-Tyrosine Kinase Inhibitors Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Non-Tyrosine Kinase Inhibitors Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Non-Tyrosine Kinase Inhibitors Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Non-Tyrosine Kinase Inhibitors Consumption by Country (2017-2022)

    • Figure United States Non-Tyrosine Kinase Inhibitors Consumption and Growth Rate (2017-2022)

    • Table Europe Non-Tyrosine Kinase Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure China Non-Tyrosine Kinase Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Japan Non-Tyrosine Kinase Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure India Non-Tyrosine Kinase Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure South Korea Non-Tyrosine Kinase Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Non-Tyrosine Kinase Inhibitors Consumption Forecast by Country (2022-2028)

    • Figure United States Non-Tyrosine Kinase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Non-Tyrosine Kinase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Non-Tyrosine Kinase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Non-Tyrosine Kinase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Non-Tyrosine Kinase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Non-Tyrosine Kinase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global mTOR Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global RAF/MEK Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global CDK Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Liver Cancer Consumption and Growth Rate (2017-2022)

    • Figure Global Respiratory Cancer Consumption and Growth Rate (2017-2022)

    • Figure Global Brain Cancer Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global mTOR Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global RAF/MEK Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global CDK Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Liver Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Respiratory Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Brain Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Non-Tyrosine Kinase Inhibitors Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Non-Tyrosine Kinase Inhibitors Export by Region (Top 5 Countries) (2017-2028)

    • Table Array BioPharma (Foundation Year, Company Profile and etc.)

    • Table Array BioPharma Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Array BioPharma Non-Tyrosine Kinase Inhibitors Product and Service

    • Table Carna Biosciences (Foundation Year, Company Profile and etc.)

    • Table Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Carna Biosciences Non-Tyrosine Kinase Inhibitors Product and Service

    • Table Daiichi Sankyo (Foundation Year, Company Profile and etc.)

    • Table Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Product and Service

    • Table Onconova Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Product and Service

    • Table Jasco Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product and Service

    • Table Eternity Bioscience (Foundation Year, Company Profile and etc.)

    • Table Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eternity Bioscience Non-Tyrosine Kinase Inhibitors Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Non-Tyrosine Kinase Inhibitors Product and Service

    • Table Celgene Corporation (Foundation Year, Company Profile and etc.)

    • Table Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celgene Corporation Non-Tyrosine Kinase Inhibitors Product and Service

    • Table AstraZeneca (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Non-Tyrosine Kinase Inhibitors Product and Service

    • Table Eli Lilly (Foundation Year, Company Profile and etc.)

    • Table Eli Lilly Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Non-Tyrosine Kinase Inhibitors Product and Service

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Non-Tyrosine Kinase Inhibitors Product and Service

    • Table Roche (Foundation Year, Company Profile and etc.)

    • Table Roche Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Non-Tyrosine Kinase Inhibitors Product and Service

    • Table Astex Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product and Service

    • Table Nerviano Medical Sciences (Foundation Year, Company Profile and etc.)

    • Table Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Product and Service

    • Table Merck KGaA (Foundation Year, Company Profile and etc.)

    • Table Merck KGaA Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck KGaA Non-Tyrosine Kinase Inhibitors Product and Service

    • Table GlaxoSmithKline (GSK) (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Product and Service

    • Table Cyclacel Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US